Author | Jeffrey Jones, MD, MPH | OncLive

Author | Jeffrey Jones, MD, MPH

Articles

Dr. Jones on Studying Venetoclax in R/R CLL

February 24, 2017

Video

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

Dr. Jones on the Safety of Venetoclax in CLL

February 23, 2017

Video

Jeffrey Jones, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses a concern of venetoclax (Venclexta) in a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLL

December 22, 2016

Video

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses the results of a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia whose disease had progressed after treatment with either ibrutinib or idelalisib.

Dr. Jeffrey Jones on Long-Term Outcomes With Ibrutinib in CLL

August 16, 2016

Video

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

x